Literature DB >> 27251205

Hospital admission for hyperemesis gravidarum: a nationwide study of occurrence, reoccurrence and risk factors among 8.2 million pregnancies.

L Fiaschi1, C Nelson-Piercy2, L J Tata3.   

Abstract

STUDY QUESTION: What are the maternal risk factors for hyperemesis gravidarum (HG) hospital admission, readmission and reoccurrence in a following pregnancy? SUMMARY ANSWER: Young age, less socioeconomic deprivation, nulliparity, Asian or Black ethnicity, female fetus, multiple pregnancy, history of HG in a previous pregnancy, thyroid and parathyroid dysfunction, hypercholesterolemia and Type 1 diabetes are all risk factors for HG. WHAT IS KNOWN ALREADY: Women with Black or Asian ethnicity, of young age, carrying multiple babies or singleton females, with Type 1 diabetes or with a history of HG were previously reported to be at higher risk of developing HG; however, most evidence is from small studies. Little is known about associations with other comorbidities and there is controversy over other risk factors such as parity. Estimates of HG prevalence vary and there is a little understanding of the risks of HG readmission in a current pregnancy and reoccurrence rates in subsequent pregnancies, all of which are needed for planning measures to reduce onset or worsening of the condition. STUDY DESIGN, SIZE, DURATION: We performed a population-based cohort study of pregnancies ending in live births and stillbirths using prospectively recorded secondary care records (Hospital Episode Statistics) from England. We analysed those computerized and anonymized clinical records from over 5.3 million women who had one or more pregnancies between 1997 and 2012. PARTICIPANTS/MATERIALS, SETTING,
METHODS: We obtained 8 215 538 pregnancies from 5 329 101 women of reproductive age, with a total of 186 800 HG admissions occurring during 121 885 pregnancies. Multivariate logistic regression with generalized estimating equations was employed to estimate odds ratios (aOR) to assess sociodemographic, pregnancy and comorbidity risk factors for HG onset, HG readmission within a pregnancy and reoccurrence in a subsequent pregnancy. MAIN RESULTS AND THE ROLE OF CHANCE: Being younger, from a less socioeconomically deprived status, of Asian or Black ethnicity, carrying a female fetus or having a multiple pregnancy all significantly increased HG and readmission risk but only ethnicity increased reoccurrence. Comorbidities most strongly associated with HG were parathyroid dysfunction (aOR = 3.83, 95% confidence interval 2.28-6.44), hypercholesterolemia (aOR = 2.54, 1.88-3.44), Type 1 diabetes (aOR = 1.95, 1.82-2.09), and thyroid dysfunction (aOR = 1.85, 1.74-1.96). History of HG was the strongest independent risk factor (aOR = 4.74, 4.46-5.05). Women with higher parity had a lower risk of HG compared with nulliparous women (aOR = 0.90, 0.89-0.91), which was not explained by women with HG curtailing further pregnancies. LIMITATIONS, REASONS FOR CAUTION: Although this represents the largest population-based study worldwide on the topic, the results could have been biased by residual and unmeasured confounding considering that some potential important risk factors such as smoking, BMI or prenatal care could not be measured with these data. Underestimation of non-routinely screened comorbidities such as hypercholesterolemia or thyroid dysfunction could also be a cause of selection bias. WIDER IMPLICATIONS OF THE
FINDINGS: The estimated prevalence of 1.5% from our study was similar to the average prevalence reported in the literature and the representativeness of our data has been validated by comparison to national statistics. Also the prevalence of comorbidities was mostly similar to other studies estimating these in the UK and other developed countries. Women with Black or Asian ethnicity, of young age, carrying multiple babies or singleton females, with Type 1 diabetes or with history of HG were confirmed to be at higher risk of HG with an unprecedented higher statistical power. We showed for the first time that socioeconomic status interacts with maternal age, that hypercholesterolemia is a potential risk factor for HG and that carrying multiple females increases risk of hyperemesis compared with multiple males. We also provided robust evidence for the association of parity with HG. Earlier recognition and management of symptoms via gynaecology day-case units or general practitioner services can inform prevention and control of consequent hospital admissions. STUDY FUNDING/COMPETING INTERESTS: The work was founded by The Rosetrees Trust and the Stoneygate Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. C.N.-P. reports personal fees from Sanofi Aventis, Warner Chilcott, Leo Pharma, UCB and Falk, outside the submitted work and she is one of the co-developers of the RCOG Green Top Guideline on HG; all other authors did not report any potential conflicts of interest. TRIAL REGISTRATION NUMBER: Not applicable.
© The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  hospital admission; hyperemesis gravidarum; pregnancy sickness; risk factors; severe nausea and vomiting in pregnancy

Mesh:

Year:  2016        PMID: 27251205     DOI: 10.1093/humrep/dew128

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  18 in total

1.  Intractable hyperemesis gravidarum in a patient with type 1 diabetes.

Authors:  Muhammad Fahad Arshad; Nasir Javed; Mohammad Bekhit
Journal:  BMJ Case Rep       Date:  2017-12-22

2.  Hyperemesis Gravidarum: Risk of Recurrence in Subsequent Pregnancies.

Authors:  Michael J Fassett; Morgan R Peltier; Adrian H Lopez; Vicki Y Chiu; Darios Getahun
Journal:  Reprod Sci       Date:  2022-09-26       Impact factor: 2.924

3.  Determinants of hyperemesis gravidarum among pregnant women attending health care service in public hospitals of Southern Ethiopia.

Authors:  Gedife Ashebir; Haymanot Nigussie; Mustefa Glagn; Kassaw Beyene; Asmare Getie
Journal:  PLoS One       Date:  2022-04-26       Impact factor: 3.752

4.  Association of Nausea and Vomiting During Pregnancy With Pregnancy Loss: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Stefanie N Hinkle; Sunni L Mumford; Katherine L Grantz; Robert M Silver; Emily M Mitchell; Lindsey A Sjaarda; Rose G Radin; Neil J Perkins; Noya Galai; Enrique F Schisterman
Journal:  JAMA Intern Med       Date:  2016-11-01       Impact factor: 21.873

5.  Rating of four different foods in women with hyperemesis gravidarum: a randomised controlled trial.

Authors:  Gi Ni Tan; Peng Chiong Tan; Jesrine Gek Shan Hong; Balaraman Kartik; Siti Zawiah Omar
Journal:  BMJ Open       Date:  2021-05-13       Impact factor: 2.692

Review 6.  Hyperemesis Gravidarum is associated with substantial economic burden in addition to severe physical and psychological suffering.

Authors:  Jone Trovik; Åse Vikanes
Journal:  Isr J Health Policy Res       Date:  2016-10-10

7.  Effect of Nausea and Vomiting on Anxiety and Depression Levels in Early Pregnancy.

Authors:  Fatma Beyazit; Basak Sahin
Journal:  Eurasian J Med       Date:  2018-06-01

8.  The Contribution of Registered Dietitians in the Management of Hyperemesis Gravidarum in the United Kingdom.

Authors:  Kate Maslin; Hazel A Billson; Caitlin R Dean; Julie Abayomi
Journal:  Nutrients       Date:  2021-06-08       Impact factor: 5.717

9.  Associations of vomiting and antiemetic use in pregnancy with levels of circulating GDF15 early in the second trimester: A nested case-control study.

Authors:  Clive J Petry; Ken K Ong; Keith A Burling; Peter Barker; Sandra F Goodburn; John R B Perry; Carlo L Acerini; Ieuan A Hughes; Rebecca C Painter; Gijs B Afink; David B Dunger; Stephen O'Rahilly
Journal:  Wellcome Open Res       Date:  2018-09-21

10.  Women with prolonged nausea in pregnancy have increased risk for depressive symptoms postpartum.

Authors:  Stavros I Iliadis; Cathrine Axfors; Sara Johansson; Alkistis Skalkidou; Ajlana Mulic-Lutvica
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.